LivaNova's (LIVN) "Buy" Rating Reiterated at Needham & Company LLC

Key Points

• Needham & Company LLC reaffirmed its "Buy" rating for LivaNova (NASDAQ:LIVN) with a target price of $64.00, reflecting a potential upside of 12.44% based on the stock's previous close.
• Several analysts have recently upgraded LivaNova's stock ratings, with Wolfe Research progressing from "peer perform" to "outperform," setting a price target of $60.00.
• LivaNova reported a quarterly EPS of $1.05, surpassing analysts' estimates, and showcased a revenue increase of 10.6% year-over-year, totaling $352.50 million.

LivaNova (NASDAQ:LIVN - Get Free Report)'s stock had its "buy" rating reaffirmed by Needham & Company LLC in a report issued on Wednesday,Benzinga reports. They presently have a $64.00 price target on the stock. Needham & Company LLC's price target indicates a potential upside of 10.40% from the company's previous close.

Several other equities research analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a research note on Tuesday, May 20th. Robert W. Baird upped their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Barclays upped their target price on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $59.71.

LivaNova Trading Down 0.3%

LIVN traded down $0.18 during trading on Wednesday, hitting $57.97. 958,459 shares of the company's stock were exchanged, compared to its average volume of 633,219. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. LivaNova has a 1 year low of $32.48 and a 1 year high of $58.42. The stock has a 50 day moving average price of $48.67 and a 200 day moving average price of $43.65. The firm has a market cap of $3.17 billion, a P/E ratio of -14.90 and a beta of 0.97.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. During the same period in the previous year, the firm earned $0.93 earnings per share. LivaNova's revenue for the quarter was up 10.6% on a year-over-year basis. As a group, analysts expect that LivaNova will post 2.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. State of Wyoming bought a new position in LivaNova during the 2nd quarter valued at $31,000. Nomura Holdings Inc. bought a new position in LivaNova during the 2nd quarter valued at $3,918,000. Headlands Technologies LLC boosted its stake in LivaNova by 270.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,456 shares of the company's stock valued at $156,000 after acquiring an additional 2,524 shares during the last quarter. Captrust Financial Advisors bought a new position in LivaNova during the 2nd quarter valued at $218,000. Finally, Scopia Capital Management LP bought a new position in LivaNova during the 2nd quarter valued at $36,657,000. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.